{"id":"idegasp","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypoglycemia"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Weight gain"},{"rate":null,"effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"IDegAsp combines insulin degludec (a ultra-long-acting basal insulin) with insulin aspart (a rapid-acting insulin). Insulin degludec provides steady, 24-hour glucose control, while insulin aspart addresses postprandial (after-meal) glucose spikes. This combination allows patients to achieve glycemic control with a simplified twice-daily injection regimen.","oneSentence":"IDegAsp is a fixed-ratio combination insulin that provides both long-acting basal insulin coverage and rapid-acting mealtime insulin in a single injection.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:15:30.138Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"},{"name":"Type 1 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT07173712","phase":"PHASE4","title":"Regimen Transition After Short-Term Intensive Insulin Therapy in Type 2 Diabetes","status":"NOT_YET_RECRUITING","sponsor":"Yanbing Li","startDate":"2026-03-15","conditions":"Type 2 Diabetes","enrollment":324},{"nctId":"NCT05417841","phase":"NA","title":"Safety and Efficacy of Insulin Degludec/Insulin Aspart in Patients With T2DM","status":"COMPLETED","sponsor":"Beijing Hospital","startDate":"2023-03-23","conditions":"Type 2 Diabetes Mellitus","enrollment":218},{"nctId":"NCT05413369","phase":"PHASE3","title":"iGlarLixi vs IDegAsp in Chinese Participants After OAD(s)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2022-07-07","conditions":"Type 2 Diabetes Mellitus","enrollment":582},{"nctId":"NCT06199505","phase":"PHASE2","title":"A Trial Comparing Efficacy and Safety of GZR101 and IDegAsp in Insulin Naïve or Insulin Treated Subjects with T2DM","status":"COMPLETED","sponsor":"Gan and Lee Pharmaceuticals, USA","startDate":"2023-11-21","conditions":"Type 2 Diabetes","enrollment":153},{"nctId":"NCT05221580","phase":"","title":"China Research of IDEgAsp Treatment in Real-world Clinical practicE (CREATE)","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2022-03-18","conditions":"Diabetes Mellitus, Type 2","enrollment":887},{"nctId":"NCT04965051","phase":"NA","title":"Safety and Efficacy of Insulin Degludec/Insulin Aspart in Patients With T1DM","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2021-08","conditions":"Type 1 Diabetes Mellitus With Diabetic Gastroparesis, HbA1c, Time in Range","enrollment":40},{"nctId":"NCT02844790","phase":"PHASE1","title":"A Trial Investigating the Pharmacokinetic Properties of Insulin Degludec/Insulin Aspart in Healthy Chinese Subjects","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2016-07-26","conditions":"Healthy","enrollment":24},{"nctId":"NCT02906917","phase":"PHASE3","title":"A 38 Week Trial Comparing Effect and Safety of Insulin Degludec/Insulin Aspart vs. Insulin Glargine Plus Insulin Aspart in Subjects With Type 2 Diabetes Treated With Basal Insulin With or Without Oral Antidiabetic Treatment in Need of Treatment Intensification","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2016-09-20","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":532},{"nctId":"NCT02762578","phase":"PHASE3","title":"Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart and BIAsp 30 in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2016-05-03","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":543},{"nctId":"NCT01513590","phase":"PHASE3","title":"A Trial Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart and BIAsp 30 in Insulin naïve Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2012-01-16","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":394},{"nctId":"NCT01059812","phase":"PHASE3","title":"A Pan Asian Trial Comparing Efficacy and Safety of NN5401 and Biphasic Insulin Aspart 30 in Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2010-02-01","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":424},{"nctId":"NCT01009580","phase":"PHASE3","title":"Comparison of NN5401 With Biphasic Insulin Aspart 30 in Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2009-11-05","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":447},{"nctId":"NCT02648217","phase":"PHASE3","title":"Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart Twice Daily and Biphasic Insulin Aspart Twice Daily in Subjects With Type 2 Diabetes Mellitus Before, During and After Ramadan","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2016-01-04","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":263},{"nctId":"NCT01680341","phase":"PHASE3","title":"Comparison of the Efficacy and Safety of Two Different Dose Adjustment Regimens for Insulin Degludec/Insulin Aspart in Subjects With Type 2 Diabetes Mellitus Previously Treated With Insulin Glargine","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2012-08-31","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":272},{"nctId":"NCT01713530","phase":"PHASE3","title":"A 26-week Trial Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart BID and Insulin Degludec OD Plus Insulin Aspart in Subjects With Type 2 Diabetes Mellitus Treated With Basal Insulin in Need of Treatment Intensification With Mealtime Insulin","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2013-02-21","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":274},{"nctId":"NCT01814137","phase":"PHASE3","title":"A Randomised Trial Comparing Efficacy and Safety After Intensification With Either Insulin Aspart Once Daily as add-on or Changing to Basal Bolus Treatment With Insulin Degludec and Insulin Aspart in Subjects With Type 2 Diabetes Previously Treated With Insulin Degludec/Insulin Aspart Twice Daily","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2013-03","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":40},{"nctId":"NCT00978627","phase":"PHASE3","title":"Comparison of NN5401 Plus Insulin Aspart With Insulin Detemir Plus Insulin Aspart in Type 1 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2009-08","conditions":"Diabetes, Diabetes Mellitus, Type 1","enrollment":548},{"nctId":"NCT01045447","phase":"PHASE3","title":"Comparison of NN5401 With Insulin Glargine, Both in Combination With Oral Antidiabetic Drugs, in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2010-01","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":465},{"nctId":"NCT01272193","phase":"PHASE3","title":"Comparison of NN5401 With Insulin Glargine in Insulin Naive Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2011-01","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":296},{"nctId":"NCT01365507","phase":"PHASE3","title":"Efficacy and Safety of Insulin Degludec/Insulin Aspart in Insulin-naïve Subjects With Type 2 Diabetes Using Two Dosing Regimens","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2011-06","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":276},{"nctId":"NCT01174303","phase":"PHASE1","title":"A Trial Investigating the Exposure of NN5401 in Young Adults and Elderly Subjects With Type 1 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2010-08","conditions":"Diabetes, Diabetes Mellitus, Type 1","enrollment":28},{"nctId":"NCT01051102","phase":"PHASE1","title":"Effect of NN5401 in Japanese Subjects With Type 1 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2010-01","conditions":"Diabetes, Diabetes Mellitus, Type 1","enrollment":21},{"nctId":"NCT01590836","phase":"PHASE1","title":"A Trial Investigating the Pharmacodynamic Properties of NN5401 in Subjects With Type 1 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2012-04","conditions":"Diabetes, Diabetes Mellitus, Type 1","enrollment":22},{"nctId":"NCT00993096","phase":"PHASE1","title":"Investigation of the Response Relationship of NN5401 in Type 1 Diabetics","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2009-09","conditions":"Diabetes, Diabetes Mellitus, Type 1","enrollment":33},{"nctId":"NCT01045707","phase":"PHASE3","title":"Comparison of NN5401 Versus Insulin Glargine, Both Combined With Metformin Treatment, in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2010-01","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":530},{"nctId":"NCT01865331","phase":"PHASE1","title":"Safety, Tolerability and Pharmacokinetic and Pharmacodynamic Characteristics of Explorative Formulations of Insulin Degludec and IDegAsp 50 in Healthy Japanese Subjects","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2006-12","conditions":"Diabetes, Healthy","enrollment":32},{"nctId":"NCT01868581","phase":"PHASE1","title":"Bioequivalence Between Two Explorative Insulin Degludec Formulations and Between Two Explorative IDegAsp Formulations in Healthy Subjects","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2008-05","conditions":"Diabetes, Healthy","enrollment":58},{"nctId":"NCT01868555","phase":"PHASE1","title":"Safety, Pharmacokinetics and Pharmacodynamics of Two IDegAsp (One Explorative) Preparations and Two Insulin Degludec (One Explorative) Preparations in Japanese Subjects","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2007-12","conditions":"Diabetes, Healthy","enrollment":32},{"nctId":"NCT01868568","phase":"PHASE1","title":"Comparison of IDegAsp (Inclusive Three Explorative Formulations) With Insulin Degludec and Insulin Aspart Separately Injected in Subjects With Type 1 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2008-04","conditions":"Diabetes, Diabetes Mellitus, Type 1","enrollment":55},{"nctId":"NCT01125553","phase":"PHASE1","title":"A Comparison Between Two Formulations of NN5401 in Healthy Subjects","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2010-05","conditions":"Diabetes, Healthy","enrollment":26},{"nctId":"NCT01773798","phase":"PHASE1","title":"A Trial Investigating the Pharmacodynamic and Pharmacokinetic Properties of Insulin Degludec/Insulin Aspart 15 in Subjects With Type 1 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2013-01","conditions":"Diabetes, Diabetes Mellitus, Type 1","enrollment":33},{"nctId":"NCT01455142","phase":"PHASE1","title":"A Trial to Test for Bioequivalence Between NN1045 and NN5401 in Subjects With Type 1 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2011-10","conditions":"Diabetes, Diabetes Mellitus, Type 1","enrollment":32},{"nctId":"NCT00992537","phase":"PHASE1","title":"Comparison of the Effect of NN5401 With the Effect of NN1250 and Insulin Aspart in Type 1 Diabetics","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2009-10","conditions":"Diabetes, Diabetes Mellitus, Type 1","enrollment":27},{"nctId":"NCT01173926","phase":"PHASE1","title":"Comparison of the Effect of NN5401 With the Effect of NN1250 and Insulin Aspart in Subjects With Type 1 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2010-07","conditions":"Diabetes, Diabetes Mellitus, Type 1","enrollment":27}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"HYPOGLYCAEMIC COMA"},{"count":1,"reaction":"INSULIN C-PEPTIDE INCREASED"},{"count":1,"reaction":"INTENTIONAL OVERDOSE"},{"count":1,"reaction":"NASOPHARYNGITIS"},{"count":1,"reaction":"POLYMYALGIA RHEUMATICA"},{"count":1,"reaction":"SUICIDE ATTEMPT"}],"_approvalHistory":[],"publicationCount":121,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"IDegAsp","genericName":"IDegAsp","companyName":"Sanofi","companyId":"sanofi","modality":"Small molecule","firstApprovalDate":"","aiSummary":"IDegAsp is a fixed-ratio combination insulin that provides both long-acting basal insulin coverage and rapid-acting mealtime insulin in a single injection. Used for Type 2 diabetes mellitus, Type 1 diabetes mellitus.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}